Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.
Now, a new National Institutes of Health research grant awarded to Colleen Kelly, M.D., a gastroenterologist with the Center for Women's Gastrointestinal Medicine at the Women's Medicine Collaborative, and co-investigator Lawrence Brandt, M.D., from the Albert Einstein School of Medicine in New York, will test whether an unconventional yet promising treatment known as fecal bacteriotherapy, or fecal transplantation, is an effective therapy for patients with relapsing C. difficile.
While it sounds unpleasant, previous research suggests fecal transplantation, which involves transplanting healthy donor stool into the patient's colon during a colonoscopy, is extremely successful; according to published case studies, the procedure has "cured" relapsing C. difficile in 89 percent of patients without any complications. However, few physicians know about the procedure, which has been around for more than 50 years, and to date there have been no published prospective clinical trials of fecal transplant for C. difficile.
Kelly's research will be the first randomized controlled clinical trial of this procedure as a treatment for relapsing C. difficile.
This video is not supported by your browser at this time.
A new research grant awarded to gastroenterologist Colleen Kelly, M.D. of the Women's Medicine Collaborative in Providence will test whether an unconventional yet promising treatment known as fecal transplantation is an effective therapy for patients with relapsing C. difficile. Credit: Lifespan"Our goal is to clearly demonstrate to both the medical community and health insurers that fecal transplant is an viable, safe, inexpensive, and ultimately curative treatment for patients with relapsing C. difficile," said Kelly. "We hope this research is the first step toward developing standard treatment protocols for this procedure and making it more widely available to the many patients who are suffering from recurring C. difficle."
C. difficile affects tens of thousands of Americans each year, particularly patients in hospitals or long-term care facilities, and typically occurs after a dose of antibiotic medications. It has been increasing in both incidence and severity over the last decade, including otherwise healthy people who aren't hospitalized or taking antibiotics. It causes 14,000 deaths annually, according to the Centers for Disease Control and Prevention.
C. difficile disrupts the balance of the normal, healthy, protective bacterial flora found in the colon. When that happens often following a dose of antibiotics invasive bacteria like C. difficile can grow, proliferate and produce toxins that make patients sick.
Approximately 20 percent of patients have recurring C. difficile that does not respond to antibiotics. Patients who experience one recurrence have a 40 percent risk of further relapse, while those with two or more episodes face a 60 percent relapse risk. While the first relapse is generally treated with a second course of antibiotics, current guidelines recommend a tapering course of an expensive antibiotic known as oral vancomycin following a second recurrence.
During a fecal transplant, healthy donor stool is mixed with saline and infused into the colon during a standard outpatient colonoscopy procedure. The patient identifies the donor usually a family member or close friend ahead of time, and the donor undergoes a rigorous screening process. A stool sample is obtained the morning of the procedure.
Kelly, who is also a clinical assistant professor of medicine at The Warren Alpert Medical School of Brown University, says fecal transplant works because the donor stool contains the healthy bacteria needed to restore and repopulate the patient's colon with what she calls an "army of good bacteria" to keep C. difficle from overgrowing and causing disease.
Kelly and Brandt hope to enroll 48 patients in this randomized study, which will determine if fecal transplantation, using stool from a healthy volunteer donor, provides a cure for relapsing C. difficile infection. Collaborating investigators at the University of Minnesota will analyze the complex bacterial communities in stool collected from patients both before and after transplant, as well as their donors.
"Given the increasing incidence and severity of C. difficile infection, the problem of recurrent disease in a significant number of patients, and the economic burden and drug-resistant infections associated with long term use of oral antibiotics, we need this clinical trial to determine whether fecal transplant is an effective treatment for relapsing infection," said Kelly.
Provided by Lifespan
- A new treatment option for Clostridium difficile: Fecal transplantation Mar 14, 2012 | not rated yet | 0
- Fecal transplant feasible for recurrent <i>C. difficile</i> infection Mar 03, 2012 | not rated yet | 0
- Synthetic stool a prospective treatment for C. difficile Apr 30, 2012 | not rated yet | 0
- Fecal microbiota transplants effective treatment for C. difficile, Inflammatory Bowel Disease Oct 31, 2011 | not rated yet | 0
- University of Minnesota startup to treat challenging bacterial infection May 16, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.
Diseases, Conditions, Syndromes 17 hours ago | not rated yet | 0
(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.
Diseases, Conditions, Syndromes 18 hours ago | not rated yet | 0
(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.
Diseases, Conditions, Syndromes 19 hours ago | not rated yet | 0
Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.
Diseases, Conditions, Syndromes 22 hours ago | not rated yet | 0
The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.
Diseases, Conditions, Syndromes May 24, 2013 | 5 / 5 (1) | 0
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
1 hour ago | not rated yet | 1
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
1 hour ago | not rated yet | 2
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
57 minutes ago | not rated yet | 0
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
1 hour ago | not rated yet | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
22 hours ago | 5 / 5 (3) | 0 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
17 hours ago | 3 / 5 (2) | 0 |